









Markets
/
Stocks
/
nasdaq-immx
/

Immix Biopharma Inc

IMMX



View Detailed Chart

5.810USD

+0.090+1.57%

Close 12/22, 16:00（ET）Quotes delayed by 15 min

191.94MMarket Cap

LossP/E TTM



Immix Biopharma Inc

5.810

+0.090+1.57%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+1.57%

5 Days

-6.37%

1 Month

+34.18%

6 Months

+159.38%

Year to Date

+164.09%

1 Year

+167.74%

View Detailed Chart

TradingKey Stock Score of Immix Biopharma Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immix Biopharma Inc's Score

Industry at a Glance

Industry Ranking

236 / 501

Overall Ranking

422 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

12.000

Target Price

+95.12%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Immix Biopharma Inc Highlights

StrengthsRisks

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -4.34, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.76M shares, decreasing 41.12% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 698.54K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.15.